Reports
Sale
Europe Respiratory Inhalers Market Size, Share, Analysis: By Product Type: Dry Powdered Inhalers, Metered Dose Inhalers, Nebulizers, Others; By Technology: Manually Operated Inhaler, Digitally Operated Inhaler; By Indication: Asthma, COPD, Others; By Distribution Channel; By End Use; Regional Analysis; Supplier Landscape; 2024-2032
Europe Respiratory Inhalers Market Outlook
The global respiratory inhalers market size was valued at USD 33.5 billion in 2023, with Europe holding a significant market share. It is driven by the increasing number of respiratory disease cases in the region. The market is expected to grow at a CAGR of 5.4% during the forecast period of 2024-2032, and attain a value of USD 53.9 billion by 2032.
Key Takeaways
- In March 2024, Boehringer Ingelheim made an investment to improve the affordability and access of inhaler products for COPD and asthma patients by capping out-of-pocket cost at USD 35 per month. Such initiatives, aimed at providing affordable resources to the consumers is one of the notable Europe respiratory inhalers market trends.
- In March 2023, Teva Pharmaceuticals collaborated with Rimidi, for a respiratory patient monitoring program. Increasing collaborations and partnerships are poised to drive the market growth during the forecast period.
- The market is witnessing an influx of new and innovative devices. In July 2023, Lupin unit launched pressurized metered dose inhalers in Germany.
Europe Respiratory Inhalers Market Analysis
Respiratory inhalers are used to breathe in medication in case of chronic lung diseases. Air pollution is one of the major reasons for the increase of respiratory diseases. The Organization for Economic Co-operation and Development (OECD) projects the global greenhouse gas emissions to increase by 50%, majorly due to 70% increase in energy related CO2 emissions. As a result, respiratory diseases such as asthma, COPD and bronchitis are projected to increase in the forecast period, fuelling the Europe respiratory inhalers market demand significantly.
According to World Health Organization (WHO), asthma is a noncommunicable and most chronic disease among children. Medication taken via inhalation can curb the symptoms and allow the patient to live a normal life. Consequently, the application of inhalers to provide effective solutions to patients belonging to diverse age groups is likely to drive the Europe respiratory inhalers market growth in the forecast period.
The market is expanding with increasing collaborations in the region. In January 2024, Inhalation Sciences and Actarmo, a Germany based company entered a collaboration for respiratory drug development services. The deal between the two organizations comprises of preclinical in vitro and in vivo pharmacokinetics studies, involving testing of devices and the complete development of inhalational combination assets. In July 2023, Hormosan Pharma GmbH, a subsidiary of Lipun introduced pressurized metered dose inhalers, Luforbec for the treatment of COPD and asthma in Germany. Luforbec is a combination of corticosteroid and long-acting beta 2 agonist. Increasing incidence of strategic mergers and collaborations aimed at improving patient outcomes is likely to augment Europe respiratory inhalers market share in the coming years.
Few of the inhalers in the European region are Neovent, Salamol, Ventolin, and Easyhaler among Others. The market share is also fuelled by the advent of smart and digital inhalers, along with the development of eco-friendly solutions. In March 2023, Teva Pharmaceuticals partnered with Rimidi to launch a respiratory patient monitoring program with the help of Teva’s Digihaler System. Increasing public awareness around the early diagnosis for respiratory conditions, along with campaigns around using inhalers with ease are amongst major market trends.
Europe Respiratory Inhalers Market Segmentation
The report offers a detailed analysis of the market based on the following segments:
| Market Breakup | Categories |
| Product Type | Dry Powdered Inhalers (Multi-Dose Dry Powder Inhalers, Single Dose Dry Powder Inhalers), Metered Dose Inhalers (Pressured Metered Dose Inhalers, Connected Metered Dose Inhalers); Nebulizers (Compressed Air Nebulizers, Mesh Air Nebulizers, Ultrasonic Air Nebulizers) |
| Technology | Manually Operated Inhaler, Digitally Operated Inhaler |
| Indication | Asthma, COPD, Pulmonary Arterial Hypertension, Other Respiratory Disease |
| Distribution Channel | Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies |
| End Use | Hospitals and Clinics, Homecare Settings, Respiratory Care Centers |
| Countries | United Kingdom, Germany, France, Italy |
Europe Respiratory Inhalers Market: Competitor Landscape
The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- AstraZeneca Plc
- Beximco Pharmaceuticals Ltd.
- Boehringer Ingelheim International GmbH
- Cipla Ltd
- GSK Plc
- Koninklijke Philips NV
- OMRON Corp
- PARI Respiratory Equipment, Inc
- OPKO Health, Inc
- Teva Pharmaceutical Industries Ltd
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product Type |
|
| Breakup by Technology |
|
| Breakup by Indication |
|
| Breakup by Distribution Channel |
|
| Breakup by End Use |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Europe Respiratory Inhalers Market Overview
3.1 Europe Respiratory Inhalers Market Historical Value (2017-2023)
3.2 Europe Respiratory Inhalers Market Forecast Value (2024-2032)
4 Europe Respiratory Inhalers Market Landscape*
4.1 Europe Respiratory Inhalers Market: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Europe Respiratory Inhalers Market: Product Landscape
4.2.1 Analysis by Product
4.2.2 Analysis by Material
4.2.3 Analysis by Type
5 Europe Respiratory Inhalers Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter’s Five Forces Analysis
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Europe Respiratory Inhalers Market Segmentation (2017-2032)
6.1 Europe Respiratory Inhalers Market (2017-2032) by Product Type
6.1.1 Market Overview
6.1.2 Dry Powdered Inhalers
6.1.2.1 Multi-Dose Dry Powder Inhalers
6.1.2.2 Single Dose Dry Powder Inhalers
6.1.3 Metered Dose Inhalers
6.1.3.1 Pressured Metered Dose Inhalers
6.1.3.2 Connected Metered Dose Inhalers
6.1.4 Nebulizers
6.1.4.1 Compressed Air Nebulizers
6.1.4.2 Mesh Air Nebulizers
6.1.4.3 Ultrasonic Air Nebulizers
6.1.4.4 Others
6.1.5 Others
6.2 Europe Respiratory Inhalers Market (2017-2032) by Technology
6.2.1 Market Overview
6.2.2 Manually Operated Inhaler
6.2.3 Digitally Operated Inhaler
6.3 Europe Respiratory Inhalers Market (2017-2032) by Indication
6.3.1 Market Overview
6.3.2 Asthma
6.3.3 COPD
6.3.4 Pulmonary Arterial Hypertension
6.3.5 Other Respiratory Diseases
6.4 Europe Respiratory Inhalers Market (2017-2032) by Distribution Channel
6.4.1 Market Overview
6.4.2 Hospital Pharmacies
6.4.3 Retail Pharmacies
6.4.4 Online Pharmacies
6.5 Europe Respiratory Inhalers Market (2017-2032) by End Use
6.5.1 Market Overview
6.5.2 Hospitals & Clinics
6.5.3 Homecare Settings
6.5.4 Respiratory Care Centers
6.5.5 Others
6.6 Europe Respiratory Inhalers Market (2017-2032) by Countries
6.6.1 Market Overview
6.6.2 United Kingdom
6.6.3 Germany
6.6.4 France
6.6.5 Italy
7 United Kingdom Respiratory Inhalers Market (2017-2032)
7.1 United Kingdom Respiratory Inhalers Market (2017-2032) by Product Type
7.1.1 Market Overview
7.1.2 Dry Powdered Inhalers
7.1.2.1 Multi-Dose Dry Powder Inhalers
7.1.2.2 Single Dose Dry Powder Inhalers
7.1.3 Metered Dose Inhalers
7.1.3.1 Pressured Metered Dose Inhalers
7.1.3.2 Connected Metered Dose Inhalers
7.1.4 Nebulizers
7.1.4.1 Compressed Air Nebulizers
7.1.4.2 Mesh Air Nebulizers
7.1.4.3 Ultrasonic Air Nebulizers
7.1.4.4 Others
7.1.5 Others
7.2 United Kingdom Respiratory Inhalers Market (2017-2032) by Technology
7.2.1 Market Overview
7.2.2 Manually Operated Inhaler
7.2.3 Digitally Operated Inhaler
7.3 United Kingdom Respiratory Inhalers Market (2017-2032) by Indication
7.3.1 Market Overview
7.3.2 Asthma
7.3.3 COPD
7.3.4 Pulmonary Arterial Hypertension
7.3.5 Others Respiratory Disease
7.4 United Kingdom Respiratory Inhalers Market (2017-2032) by Distribution Channel
7.4.1 Market Overview
7.4.2 Hospital Pharmacies
7.4.3 Retail Pharmacies
7.4.4 Online Pharmacies
7.5 United Kingdom Inhalers Market (2017-2032) by End Use
7.5.1 Market Overview
7.5.2 Hospitals & Clinics
7.5.3 Homecare Settings
7.5.4 Respiratory Care Centers
7.5.5 Others
8 Germany Respiratory Inhalers Market (2017-2032)
8.1 Germany Respiratory Inhalers Market (2017-2032) by Product Type
8.1.1 Market Overview
8.1.2 Dry Powdered Inhalers
8.1.2.1 Multi-Dose Dry Powder Inhalers
8.1.2.2 Single Dose Dry Powder Inhalers
8.1.3 Metered Dose Inhalers
8.1.3.1 Pressured Metered Dose Inhalers
8.1.3.2 Connected Metered Dose Inhalers
8.1.4 Nebulizers
8.1.4.1 Compressed Air Nebulizers
8.1.4.2 Mesh Air Nebulizers
8.1.4.3 Ultrasonic Air Nebulizers
8.1.4.4 Others
8.1.5 Others
8.2 Germany Respiratory Inhalers Market (2017-2032) by Technology
8.2.1 Market Overview
8.2.2 Manually Operated Inhaler
8.2.3 Digitally Operated Inhaler
8.3 Germany Respiratory Inhalers Market (2017-2032) by Indication
8.3.1 Market Overview
8.3.2 Asthma
8.3.3 COPD
8.3.4 Pulmonary Arterial Hypertension
8.3.5 Others Respiratory Disease
8.4 Germany Respiratory Inhalers Market (2017-2032) by Distribution Channel
8.4.1 Market Overview
8.4.2 Hospital Pharmacies
8.4.3 Retail Pharmacies
8.4.4 Online Pharmacies
8.5 Germany Respiratory Inhalers Market (2017-2032) by End Use
8.5.1 Market Overview
8.5.2 Hospitals & Clinics
8.5.3 Homecare Settings
8.5.4 Respiratory Care Centers
8.5.5 Others
9 France Respiratory Inhalers Market (2017-2032)
9.1 France Respiratory Inhalers Market (2017-2032) by Product Type
9.1.1 Market Overview
9.1.2 Dry Powdered Inhalers
9.1.2.1 Multi-Dose Dry Powder Inhalers
9.1.2.2 Single Dose Dry Powder Inhalers
9.1.3 Metered Dose Inhalers
9.1.3.1 Pressured Metered Dose Inhalers
9.1.3.2 Connected Metered Dose Inhalers
9.1.4 Nebulizers
9.1.4.1 Compressed Air Nebulizers
9.1.4.2 Mesh Air Nebulizers
9.1.4.3 Ultrasonic Air Nebulizers
9.1.4.4 Others
9.1.5 Others
9.2 France Respiratory Inhalers Market (2017-2032) by Technology
9.2.1 Market Overview
9.2.2 Manually Operated Inhaler
9.2.3 Digitally Operated Inhaler
9.3 France Respiratory Inhalers Market (2017-2032) by Indication
9.3.1 Market Overview
9.3.2 Asthma
9.3.3 COPD
9.3.4 Pulmonary Arterial Hypertension
9.3.5 Others Respiratory Disease
9.4 France Respiratory Inhalers Market (2017-2032) by Distribution Channel
9.4.1 Market Overview
9.4.2 Hospital Pharmacies
9.4.3 Retail Pharmacies
9.4.4 Online Pharmacies
9.5 France Respiratory Inhalers Market (2017-2032) by End Use
9.5.1 Market Overview
9.5.2 Hospitals & Clinics
9.5.3 Homecare Settings
9.5.4 Respiratory Care Centers
9.5.5 Others
10 Italy Respiratory Inhalers Market (2017-2032)
10.1 Italy Respiratory Inhalers Market (2017-2032) by Product Type
10.1.1 Market Overview
10.1.2 Dry Powdered Inhalers
10.1.2.1 Multi-Dose Dry Powder Inhalers
10.1.2.2 Single Dose Dry Powder Inhalers
10.1.3 Metered Dose Inhalers
10.1.3.1 Pressured Metered Dose Inhalers
10.1.3.2 Connected Metered Dose Inhalers
10.1.4 Nebulizers
10.1.4.1 Compressed Air Nebulizers
10.1.4.2 Mesh Air Nebulizers
10.1.4.3 Ultrasonic Air Nebulizers
10.1.4.4 Others
10.1.5 Others
10.2 Italy Respiratory Inhalers Market (2017-2032) by Technology
10.2.1 Market Overview
10.2.2 Manually Operated Inhaler
10.2.3 Digitally Operated Inhaler
10.3 Italy Respiratory Inhalers Market (2017-2032) by Indication
10.3.1 Market Overview
10.3.2 Asthma
10.3.3 COPD
10.3.4 Pulmonary Arterial Hypertension
10.3.5 Others Respiratory Disease
10.4 Italy Respiratory Inhalers Market (2017-2032) by Distribution Channel
10.4.1 Market Overview
10.4.2 Hospital Pharmacies
10.4.3 Retail Pharmacies
10.4.4 Online Pharmacies
10.5 Italy Respiratory Inhalers Market (2017-2032) by End User
10.5.1 Market Overview
10.5.2 Hospitals & Clinics
10.5.3 Homecare Settings
10.5.4 Respiratory Care Centers
10.5.5 Others
11 Regulatory Framework
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Funding and Investment Analysis
13.1 Analysis by Funding Instances
13.2 Analysis by Type of Funding
13.3 Analysis by Funding Amount
13.4 Analysis by Leading Players
13.5 Analysis by Leading Investors
13.6 Analysis by Geography
14 Partnership and Collaborations Analysis
14.1 Analysis by Partnership Instances
14.2 Analysis by Type of Partnership
14.3 Analysis by Leading Players
14.4 Analysis by Geography
15 Supplier Landscape
15.1 Market Share by Top 5 Companies
15.2 AstraZeneca Plc
15.2.1 Financial Analysis
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Beximco Pharmaceuticals Ltd.
15.3.1 Financial Analysis
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 Boehringer Ingelheim International GmbH
15.4.1 Financial Analysis
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 Cipla
15.5.1 Financial Analysis
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 GSK Plc.
15.6.1 Financial Analysis
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 Koninklijke Philips NV
15.7.1 Financial Analysis
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 OMRON Corp.
15.8.1 Financial Analysis
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
15.9 PARI Respiratory Equipment, Inc.
15.9.1 Financial Analysis
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.9.5 Certifications
15.10 OPKO Health, Inc
15.10.1 Financial Analysis
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
15.10.5 Certifications
15.11 Teva Pharmaceutical Industries Ltd
15.11.1 Financial Analysis
15.11.2 Product Portfolio
15.11.3 Demographic Reach and Achievements
15.11.4 Mergers and Acquisitions
15.11.5 Certifications
16 Europe Respiratory Inhalers Market – Distribution Model (Additional Insight)
16.1 Overview
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Key Opinion Leaders (KOL) Insights (Additional Insight)
18 Company Competitiveness Analysis (Additional Insight)
18.1 Very Small Companies
18.2 Small Companies
18.3 Mid-Sized Companies
18.4 Large Companies
18.5 Very Large Companies
19 Payment Methods (Additional Insight)
19.1 Government Funded
19.2 Private Insurance
19.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Key Questions Answered in the Report
The market is anticipated to be driven by the rising demand in the global market, which is expected to grow at a CAGR of 5.4% during the forecast period of 2024-2032, likely to reach a market value of USD 53.9 billion by 2032.
Increasing number of chronic respiratory disease cases, advancements in inhalation technology with digital and smart inhalers are fuelling the demand for the market.
One of the significant market trends is growth in mergers and acquisitions between organisations. For instance, in July 2023, Hormosan Pharma GmbH, a subsidiary of Lipun introduced pressurized metered dose inhalers, Luforbec, designed for COPD and asthma treatment.
Based on the technology, the market is segmented into manually operated inhaler and digitally operated inhaler.
By indication, the market is divided into asthma, COPD, pulmonary arterial hypertension, and other respiratory diseases.
The market breakup is by dry powdered inhalers, metered dose inhalers, and nebulizers, among others.
End users of the market are hospitals and clinics, homecare settings, and respiratory care centres.
The market segmentation by countries includes the United Kingdom, Germany, France, and Italy.
The key players in the market are AstraZeneca Plc, Beximco Pharmaceuticals Ltd., Boehringer Ingelheim International GmbH, Cipla Ltd, GSK Plc, Koninklijke Philips NV, OMRON Corp, PARI Respiratory Equipment, Inc., OPKO Health, Inc. and Teva Pharmaceutical Industries Ltd.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2639
$2399
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 4399
$3999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 5829
$5299
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 6929
$6299
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER